CytomX Announces Data to be Presented at the American Association for Cancer Research Annual Meeting 2016
2016年3月17日 - 5:30AM
CytomX Therapeutics (Nasdaq:CTMX), a biopharmaceutical company
developing investigational Probody™ therapeutics for the treatment
of cancer, today announced that preclinical results from its
Probody therapeutics pipeline will be presented at the upcoming
American Association for Cancer Research (AACR) Annual Meeting 2016
from April 16-20 in New Orleans, Louisiana.
“The data being presented at this year’s AACR Annual Meeting
represent the next wave of preclinical programs from our growing
pipeline of Probody therapeutics for the treatment of cancer,” said
Michael Kavanaugh, M.D., chief scientific officer of CytomX.
Abstracts to be Presented at AACR
Title: Development of a Probody drug conjugate (PDC) targeting
CD71 for the treatment of solid tumors and lymphomas
- Tuesday Apr 19, 2016 8:00 a.m. - 12:00 p.m. CDT
- Halls G-J, Poster Section 15
- Abstract 2975
Title: PD-1-targeted Probody therapeutics provide anti-tumor
efficacy and a 10-fold dose protection against systemic
autoimmunity in preclinical studies
- Tuesday Apr 19, 2016 8:00 a.m. - 12:00 p.m. CDT
- Halls G-J, Poster Section 25
- Abstract 3211
Therapeutics developed with CytomX's Probody platform are
designed to be active in the tumor while sparing healthy tissue.
Due to their specific activity in the tumor microenvironment,
Probody therapeutics directed against both validated and novel
targets enable anti-tumor efficacy with a significantly enhanced
safety window, relative to traditional antibody-based therapies.
CytomX's preclinical pipeline of wholly-owned and partnered
programs includes Probody cancer immunotherapies, Probody drug
conjugates and T-cell engaging Probody bispecifics.
About CytomX TherapeuticsCytomX is an
oncology-focused biopharmaceutical company pioneering a novel class
of investigational antibody therapeutics based on its Probody
technology platform. The company uses the platform to create
development-stage proprietary cancer immunotherapies against
clinically-validated targets, as well as to develop first-in-class
investigational cancer therapeutics against novel targets. CytomX
believes that its Probody platform has the potential to improve the
combined efficacy and safety profile of monoclonal antibody
modalities, including cancer immunotherapies, antibody drug
conjugates and T-cell-recruiting bispecific antibodies. Probody
therapeutics are designed to take advantage of unique conditions in
the tumor microenvironment to enhance the tumor-targeting features
of an antibody and reduce drug activity in healthy tissues.
Investigational Probody therapeutics are being developed that
address clinically-validated cancer targets in immuno-oncology,
such as PD-L1 against which clinical candidate CX-072 is directed,
as well as novel targets, such as CD-166, that are difficult to
drug without causing damage to healthy tissues, or toxicities. In
addition to its proprietary programs, CytomX is collaborating with
strategic partners including Bristol-Myers Squibb Company, Pfizer
Inc., The University of Texas MD Anderson Cancer Center and
ImmunoGen, Inc. For more information, visit www.cytomx.com.
Forward-Looking StatementsThis press release
includes forward-looking statements. Such forward-looking
statements involve known and unknown risks, uncertainties and other
important factors that are difficult to predict, may be beyond our
control, and may cause the actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied in such
statements. Accordingly, you should not rely on any of these
forward-looking statements. Our Probody platform is in preclinical
development, and the process by which a preclinical technology
could potentially lead to an approved product is long and subject
to significant risks and uncertainties. Applicable risks and
uncertainties include those relating to our preclinical research
and development and other risks identified under the heading "Risk
Factors" included in our filings with the SEC. The forward-looking
statements contained in this press release are based on information
currently available to CytomX and speak only as of the date on
which they are made. CytomX does not undertake and specifically
disclaims any obligation to update any forward-looking statements,
whether as a result of any new information, future events, changed
circumstances or otherwise.
PROBODY is a trademark of CytomX Therapeutics, Inc.
Corporate Communications Contacts:
Canale Communications
Ian Stone
ian@canalecomm.com
619-849-5388
Investor Contacts:
Trout Group
Pete Rahmer
prahmer@troutgroup.com
646-378-2973
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 6 2024 まで 7 2024
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 7 2023 まで 7 2024